E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
squamous non-small cell lung cancer (SQ-NSCLC) |
Pacientes con cáncer de pulmón no microcítico escamoso localmente avanzado irresecable o metastásico |
|
E.1.1.1 | Medical condition in easily understood language |
Squamous non small cell lung cancer harbouring HRAS mutation |
Pacientes con cancer de pulmon no microcitico escamoso con mutación HRAS |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10025044 |
E.1.2 | Term | Lung cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To determine the antitumor activity in terms of objective response rate (ORR) of tipifarnib in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, squamous non-small cell lung cancer (SQ-NSCLC) with HRAS mutations. This objective will be evaluated in the treatment phase of the study. |
Determinar la actividad antitumoral en los términos de la tasa de respuesta objetiva de tipifarnib en sujetos con cáncer de pulmón no microcítico escamoso (SQ-NSCLC) localmente avanzado no resecable o metastásico, recidivante y/o refractario con mutaciones HRAS |
|
E.2.2 | Secondary objectives of the trial |
- To determine the frequency of HRAS mutations in squamous non-small cell lung cancer (SQ-NSCLC). This objective will be evaluated in the pre-screening phase of the study - Safety and tolerability of tipifarnib in subjects with locally advanced unresectable or metastatic, relapsed and/or refractory, squamous non-small cell lung cancer (SQ-NSCLC) with HRAS mutations. This objective will be evaluated in the treatment phase of the study |
- Determinar la frecuencia de mutaciones HRAS en cáncer de pulmón no microcítico escamoso. Este objetivo será evaluado in la fase de pre-screening del estudio. - La seguridad y la tolerabilidad de tipifarnib en sujetos con cáncer de pulmón no microcítico escamoso (SQ-NSCLC) localmente avanzado no resecable o metastásico, recidivante y/o refractario con mutaciones HRAS. Este objetico será evaluado en la fase de tratamiento del estudio |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Histologically or cytologically confirmed diagnosis of squamous non-small cell lung cancer (SQ-NSCLC) for which there is no curative therapy available. - Relapsed of disease (progressive disease) or is refractory to one or more prior therapies. In the case of therapy received in the adjuvant or neo-adjuvant setting, relapse must have occurred within 12 months to be considered prior therapy. - A tumor that carries a missense HRAS mutation. - Consent to provide tumor slides (or tumor tissue blocks) for biomarker evaluation. - Subject has measurable disease according to RECIST v1.1. - At least 2 weeks since the last systemic therapy regimen prior to enrolment. - At least 2 weeks since last radiotherapy. If radiation was localized to the only site of measurable disease, there must be documentation of disease progression of the irradiated site. Subjects must have recovered from all acute toxicities from radiotherapy. - ECOG performance status of 0 or 1. |
- Carcinoma no microcítico de pulmón comprobado por el análisis histológico o citológico para el cual no hay terapia curativa disponible. - Recaída de la enfermedad (enfermedad progresiva) o ser refractario a una o más terapias anteriores. En el caso de la terapia recibida en el entorno adyuvante o neoadyuvante, la recaída debe haber ocurrido dentro de los 12 meses para considerarse terapia previa. - Haber tumor con mutación HRAS. - Consentimiento para proporcionar láminas tumorales (o bloques de téjido tumoral) para la evaluación de biomarcadores. - Tener una enfermedad mensurable de acuerdo con RECIST v1.1. - Al menos 2 semanas desde la última terapia sistémica antes de la inscripción. - Al menos 2 semanas desde la última radioterapia. Si la radiación fue localizada en un único lugar de la enfermedad mensurable, debería haber documentación sobre la progresión de la enfermedad en el lugar irradiado. Los sujetos deberán haberse recuperado de todas las toxicidades de la radioterapia. - Categoría funcional ECOG de 0 o 1. |
|
E.4 | Principal exclusion criteria |
- Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study. - The subject has legal incapacity or limited legal capacity. - Significantly altered mental status that would limit the understanding or rendering of informed consent and compliance with the requirements of this protocol. Unwillingness or inability to comply with the study protocol for any reason. |
- Enfermedad concomitante o condición que podría interferir en la realización del estudio, o que en opinión del investigador, podría suponer un riesgo para el sujeto del estudio. - Sujeto incapacitado legalmente o tener limitada su capacidad. - Estado mental significativamente alterado que limitaría la comprensión o la prestación del consentimiento informado y el cumplimiento de los requisitos de este protocolo. Falta de voluntad o incapacidad para cumplir con el protocolo por cualquier motivo. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Response assessments according to RECIST 1.1 |
Evaluaciones de respuesta según RECIST 1.1 |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Will be evaluated in the treatment phase of the study |
Será evaluado en la fase de tratamiento del estudio |
|
E.5.2 | Secondary end point(s) |
- Molecular analyses of tumor and/or cell free DNA samples - Treatment-emergent adverse events (TEAE) and SAEs evaluated according to NCI CTCAE v.4.03 |
- Análisis molecular de muestras de ADN libres de tumor y/o células - Acontecimientos adversos emergentes del tratamiento (TEAE) y SAE evaluados de acuerdo con NCI CTCAE v.4.03 |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
- The first secondary end point will be evaluated in the pre-screening phase of the study - The second secondary end point will be evaluated in the treatment phase of the study |
- El primer end point secundario será evaluado en la fase de pre-screening del estudio - El segundo end point secundario será evaluado en la fase de tratamiento del estudio |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 30 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Ultima visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial months | 0 |